Cue Biopharma, Inc. (CUE) Social Stream



Cue Biopharma, Inc. (CUE): $1.64

0.01 (+0.61%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

CUE BIOPHARMA INC (CUE) Price Targets From Analysts

Use the tables below to see what analysts covering CUE BIOPHARMA INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-08-17 4 $32 $26 $29 $2.62 1006.87%
2021-11-15 3 $32 $28 $30 $2.62 1045.04%
2022-01-13 4 $32 $20 $27.5 $2.62 949.62%
2022-03-18 3 $32 $20 $27.333 $2.62 943.24%
2022-03-20 3 $26 $20 $23.333 $2.62 790.57%
2022-06-07 2 $26 $20 $23 $2.62 777.86%
2022-08-05 2 $26 $10 $18 $2.62 587.02%
2022-11-15 2 $10 $9 $9.5 $2.62 262.6%
2023-03-21 3 $10 $7 $8.666 $2.62 230.76%
2023-05-10 4 $10 $7 $8.333 $2.62 218.05%
2023-11-06 4 $15 $7 $10 $2.62 281.68%
2023-11-09 4 $15 $8 $10.25 $2.62 291.22%

The Trend in the Analyst Price Target


Over the past 28 months, CUE's average price target has gone down $19.75.

CUE reports an average of 182.39% for its upside potential over the past 37 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-21 3 10 7 8.666 3.38 156.39%
2023-05-09 3 10 7 8.333 4.85 71.81%
2023-08-10 4 15 7 10.000 3.14 218.47%
2023-11-06 4 15 8 10.250 2.55 301.96%
2023-11-06 4 15 7 10.000 2.55 292.16%

CUE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 4 0 0 0 0 4

The Trend in the Broker Recommendations


CUE's average broker recommendation rating improved by 0 over the prior 17 months.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • CUE BIOPHARMA INC's upside potential (average analyst target price relative to current price) is higher than 1777.96% of all US stocks.
  • CUE has a greater number of analysts covering the stock than 159.33% of all US stocks.
  • CUE BIOPHARMA INC's variance in analysts' estimates is lower than -309.33% of Pharmaceutical Products stocks.
  • In the context of stocks in the small market cap category, CUE BIOPHARMA INC's average analyst price target is greater than 915.72% of them.

In the Pharmaceutical Products industry, ZOM, SCPH, and KALA are the three stocks most similar to CUE BIOPHARMA INC regarding the price target and analyst recommendation information presented here.

Is CUE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!